Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00642733 | A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine… | Phase 4 | terminated | Mar 25, 2008 | Hoffmann-La Roche | poor recruitment | Enrollment / accrual |
| NCT00837135 | GI-4000 With Adoptive Transfer in Pancreatic Cancer | Phase 1 | withdrawn | Feb 5, 2009 | University of Pennsylvania | Withdrawn due to transfer of Investigator | Investigator |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Phase 2 | terminated | Jun 28, 2013 | Georgetown University | Adverse Event issues. | Safety / toxicity |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT01326364 | Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT01473303 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously… | Phase 1 / Phase 2 | withdrawn | Nov 17, 2011 | Alliance for Clinical Trials in Oncology | CALGB 81003 closed about a week after it was activated because of withdrawal of support. No… | Other (stated, no rule matched) |
| NCT01094626 | Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection | N/A | withdrawn | Mar 29, 2010 | Elizabeth Hecht | Pharmaceutical company did not decide to renew contract | Sponsor / business decision |
| NCT01784081 | Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients…(iPC3) | — | withdrawn | Feb 5, 2013 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | study was closed by PI due to no accrual | Enrollment / accrual |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog… | N/A | withdrawn | Jul 30, 2013 | University of Utah | No accrual | Enrollment / accrual |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT00766636 | Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy | Phase 2 | terminated | Oct 6, 2008 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01814631 | Endoscopic Ultrasound (EUS) Processor Comparison | — | withdrawn | Mar 20, 2013 | AdventHealth | Closed at PI discretion | Other (stated, no rule matched) |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | Early Phase 1 | terminated | Oct 14, 2013 | University of Virginia | From preliminary imaging data, the study was stopped due to futility. | Efficacy / futility |
| NCT00580021 | Clinical Outcomes in Hereditary Cancer | — | withdrawn | Dec 24, 2007 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT00843830 | A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed… | Phase 1 | terminated | Feb 13, 2009 | University of Michigan Rogel Cancer Center | Study closed early secondary to inability to obtain grant funding to conduct. | Funding |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | Phase 2 | terminated | Mar 18, 2009 | Georgetown University | At interim analysis the study did not meet the response criteria to continue | Efficacy / futility |
| NCT01693276 | Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced,… | Phase 1 / Phase 2 | terminated | Sep 26, 2012 | Olugbenga Olowokure | Slow accrual | Enrollment / accrual |
| NCT01042028 | A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to… | Phase 1 / Phase 2 | terminated | Jan 5, 2010 | Per Pfeiffer | Emergence of FOLFIRINOX and slow recruitment | Enrollment / accrual |
| NCT00031837 | Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or… | Phase 3 | terminated | Jan 27, 2003 | Gary Morrow | not stated | Not stated |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00544908 | Dasatinib in Treating Patients With Stage IV Pancreatic Cancer | Phase 2 | terminated | Oct 16, 2007 | City of Hope Medical Center | Toxicity | Safety / toxicity |
| NCT00899132 | Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and… | — | terminated | May 12, 2009 | Case Comprehensive Cancer Center | Study due for continuing review | Other (stated, no rule matched) |
| NCT01598584 | Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer | Phase 2 / Phase 3 | withdrawn | May 15, 2012 | Tianjin Medical University Cancer Institute and Hospital | Gemcitabine is not the first choice for most pancreatic cancer patients nowdays | Other (stated, no rule matched) |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | Phase 1 | terminated | Jan 18, 2008 | Duke University | Low accrual, unable to meet endpoint in timely manner | Enrollment / accrual |
| NCT01754623 | GTX-RT in Borderline Resectable Pancreatic Cancer | Phase 2 | terminated | Dec 21, 2012 | H. Lee Moffitt Cancer Center and Research Institute | Lack of pre-treatment tissue to make the study plan feasible. | Other (stated, no rule matched) |
| NCT01419002 | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in…(Net-Pac) | Phase 3 | terminated | Aug 17, 2011 | CHIR-Net | lack of recruitment | Enrollment / accrual |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With… | Phase 1 | terminated | Jan 15, 2010 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01954732 | Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed… | Phase 1 | withdrawn | Oct 7, 2013 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01103128 | Validation of a Mouse Model of Pancreatic Carcinogenesis | — | terminated | Apr 14, 2010 | Columbia University | not stated | Not stated |
| NCT01080248 | Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 4, 2010 | Washington University School of Medicine | Closed due to delay by GSK | Other (stated, no rule matched) |
| NCT00176735 | Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer | N/A | terminated | Sep 15, 2005 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT02132403 | (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer(PM-01) | Phase 1 | terminated | May 7, 2014 | University of Illinois at Chicago | Drug Recall | Other (stated, no rule matched) |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are… | Phase 2 | withdrawn | Nov 15, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02159248 | Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic… | Phase 1 | withdrawn | Jun 9, 2014 | Orlando Health, Inc. | The study closed prior to enrolling any participants. | Enrollment / accrual |
| NCT01167738 | Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients…(PACT-17) | Phase 2 | terminated | Jul 22, 2010 | IRCCS San Raffaele | concern of detrimental effect | Other (stated, no rule matched) |
| NCT01094535 | Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic… | N/A | withdrawn | Mar 29, 2010 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma… | Phase 2 | withdrawn | Dec 8, 2014 | Prima BioMed Ltd | The trial has been terminated per Sponsor direction due to longer than expected clinical and… | Other (stated, no rule matched) |
| NCT01130701 | A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With…(PMABIIS) | Phase 2 | withdrawn | May 26, 2010 | University of Massachusetts, Worcester | Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which this… | Other (stated, no rule matched) |
| NCT02048943 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized… | Phase 1 | withdrawn | Jan 29, 2014 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT01927393 | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV… | N/A | withdrawn | Aug 22, 2013 | City of Hope Medical Center | Study was not funded | Funding |
| NCT01694589 | A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas… | Early Phase 1 | withdrawn | Sep 27, 2012 | Rutgers, The State University of New Jersey | Lack of accrual | Enrollment / accrual |
| NCT00482625 | Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed… | Phase 2 | terminated | Jun 5, 2007 | National Cancer Institute (NCI) | The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply,… | Drug supply |
| NCT00660348 | Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally… | N/A | terminated | Apr 17, 2008 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT01362582 | Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With…(PANUSCO) | Phase 3 | terminated | May 30, 2011 | National Center for Tumor Diseases, Heidelberg | not stated | Not stated |
| NCT01760694 | Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable… | N/A | terminated | Jan 4, 2013 | Southwestern Regional Medical Center | Lack of enrollment | Enrollment / accrual |
| NCT01227018 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | Phase 2 | terminated | Oct 22, 2010 | Vanderbilt-Ingram Cancer Center | interim analysis found the study drug to be ineffective | Efficacy / futility |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With… | Phase 1 | withdrawn | Dec 5, 2012 | City of Hope Medical Center | PI chose to close the study | Other (stated, no rule matched) |
| NCT00003085 | Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer | Phase 2 | terminated | Jun 16, 2004 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00159471 | Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in… | N/A | terminated | Sep 12, 2005 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01167816 | Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic… | Phase 1 | terminated | Jul 22, 2010 | University of Oklahoma | The study was terminated as the Prinicipal Investigator left the site- all previous subjects… | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 24, 2016source: clinicaltrials